<DOC>
	<DOCNO>NCT02499120</DOCNO>
	<brief_summary>The purpose study determine whether combination palbociclib cetuximab superior cetuximab prolong overall survival HPV-negative , cetuximab-naive patient recurrent/metastatic squamous cell carcinoma head neck .</brief_summary>
	<brief_title>Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Key Histologically cytologically confirm squamous cell carcinoma oral cavity , oropharynx , hypopharynx larynx , amenable salvage surgery radiotherapy . Measurable disease define per RECIST v. 1.1 . Tumor lesion previously irradiate subjected locoregional therapy deem measureable disease progression treat site completion therapy clearly document . HPV negative SCCHN tumor determine per institutional standard ( eg , p16 IHC ; multiplex nucleic acid sequence base amplification [ NASBA ] polymerase chain reaction [ PCR ] base assay ) . Documented progressive disease accord RECIST v1.1 ( Appendix 2 ) follow receipt least 2 cycle one platinumcontaining chemotherapy regimen administer R/M disease ( min . 50 mg/m2 cisplatin , minimum area curve [ AUC ] &gt; 4 carboplatin ) . Availability tumor tissue specimen ( ie , archive formalin fix paraffin embed tissue [ block prefer , 15 unstained slide ] ) , use centralize , retrospective biomarker analysis . If archive tumor tissue available , de novo biopsy require patient participation . Key Prior nasopharyngeal cancer , salivary gland sinus tumor . More one chemotherapeutic regimen give R/M disease . Prior treatment immunotherapy allow . Known active uncontrolled symptomatic central nervous system ( CNS ) metastases , carcinomatous meningitis , leptomeningeal disease indicate clinical symptom , cerebral edema , and/or progressive growth . Patients history CNS metastases cord compression eligible definitively treated local therapy ( eg , radiotherapy , stereotactic surgery ) clinically stable anticonvulsant steroid least 4 week randomization . Progressive disease within 3 month completion curatively intend treatment locoregionally advance SCCHN . Difficulty swallow capsule . Prior use cetuximab R/M disease treatment set ( except cetuximab curative radiotherapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>palbociclib , cetuximab , human papillomavirus , squamous cell carcinoma , head neck cancer</keyword>
</DOC>